Padmanabh Bhatt Sells 50,000 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $50.28, for a total value of $2,514,000.00. Following the completion of the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $856,972.32. This represents a 74.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $48.84 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The company has a 50 day simple moving average of $51.18 and a two-hundred day simple moving average of $49.17. The company has a market capitalization of $2.81 billion, a PE ratio of -71.82, a P/E/G ratio of 1.53 and a beta of 0.70.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. boosted its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $237,000. Sit Investment Associates Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 250 shares in the last quarter. Invesco Ltd. raised its position in shares of Supernus Pharmaceuticals by 9.4% during the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock worth $19,669,000 after purchasing an additional 33,895 shares during the period. Finally, Mackenzie Financial Corp bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $223,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SUPN shares. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.